Healthcare Industry News: hemophilia A
News Release - March 27, 2012
Durata Therapeutics Appoints John P. Shannon as Chief Commercial Officer with Responsibility to Build Commercial TeamMORRISTOWN, N.J.--(Healthcare Sales & Marketing Network)--Durata Therapeutics today announced the Company has appointed John P. Shannon, former senior executive at Baxter Healthcare, to the newly created position of Chief Commercial Officer. Mr. Shannon brings to Durata over 25 years’ experience in the pharmaceutical and healthcare industry with a diverse background in sales, global and US marketing, strategic planning, business development and general management. Reporting to Durata Chief Executive Officer, Paul R. Edick, Mr. Shannon will be responsible for building out the Company’s commercial team in anticipation of FDA regulatory filing for Durata’s lead product candidate, dalbavancin, now in two pivotal clinical trials.
Mr. Edick commented, “John’s joining the Durata team signifies the next important step in our evolution as we prepare for commercialization of our lead product. John’s senior leadership experience in the infusion services arena will be an important addition to our team. We look forward to the continued success of the program and welcome Mr. Shannon to our growing team.”
Mr. Shannon joins Durata from Baxter Healthcare Corporation where he most recently served as General Manager, Global hemophilia And Global Commercial Excellence. During his tenure at Baxter, Mr. Shannon also held positions as Vice President of Marketing and General Manager of the company’s U.S. Biopharm business. Prior to Baxter, Mr. Shannon held positions of increasing responsibility at Caremark, Inc. and Searle Pharmaceutical. Mr. Shannon received his B.S. from Western Illinois University.
About Durata Therapeutics
Durata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata is developing its advanced-stage lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections.
Source: Durata Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.